2023 Q4 Form 10-Q Financial Statement
#000162828023037557 Filed on November 08, 2023
Income Statement
| Concept | 2023 Q4 | 2023 Q3 |
|---|---|---|
| Revenue | $56.20M | $42.05M |
| YoY Change | 1.84% | -14.13% |
| Cost Of Revenue | $10.51M | $18.01M |
| YoY Change | -193.41% | -52.54% |
| Gross Profit | $45.69M | $24.04M |
| YoY Change | -31.23% | 118.18% |
| Gross Profit Margin | 81.3% | 57.17% |
| Selling, General & Admin | $25.44M | $22.71M |
| YoY Change | -17.0% | -26.55% |
| % of Gross Profit | 55.68% | 94.48% |
| Research & Development | $9.865M | $13.33M |
| YoY Change | -69.08% | -51.26% |
| % of Gross Profit | 21.59% | 55.46% |
| Depreciation & Amortization | $9.404M | $9.400M |
| YoY Change | -0.16% | -0.25% |
| % of Gross Profit | 20.58% | 39.11% |
| Operating Expenses | $44.31M | $37.07M |
| YoY Change | -38.08% | -37.37% |
| Operating Profit | $1.374M | -$13.04M |
| YoY Change | -126.79% | -72.94% |
| Interest Expense | -$1.418M | -$1.410M |
| YoY Change | -13.33% | -64.32% |
| % of Operating Profit | -103.2% | |
| Other Income/Expense, Net | $658.0K | -$43.00K |
| YoY Change | 51.61% | -103.68% |
| Pretax Income | $614.0K | -$14.50M |
| YoY Change | -108.13% | -72.04% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | $614.0K | -$14.49M |
| YoY Change | -108.13% | -72.06% |
| Net Earnings / Revenue | 1.09% | -34.46% |
| Basic Earnings Per Share | -$0.08 | |
| Diluted Earnings Per Share | $0.00 | -$0.08 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 188.4M shares | 188.3M shares |
| Diluted Shares Outstanding | 188.3M shares |
Balance Sheet
| Concept | 2023 Q4 | 2023 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $42.93M | $46.50M |
| YoY Change | -52.55% | -67.88% |
| Cash & Equivalents | $42.93M | $46.53M |
| Short-Term Investments | ||
| Other Short-Term Assets | $20.24M | $22.00M |
| YoY Change | -39.65% | -25.72% |
| Inventory | $15.69M | $18.44M |
| Prepaid Expenses | $28.40M | |
| Receivables | $39.29M | $22.59M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $118.1M | $109.6M |
| YoY Change | -36.12% | -53.85% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $16.05M | $4.023M |
| YoY Change | 207.73% | -28.44% |
| Goodwill | $59.00M | $59.00M |
| YoY Change | 7.08% | 7.08% |
| Intangibles | $36.04M | $45.05M |
| YoY Change | -50.0% | |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $12.42M | $3.862M |
| YoY Change | 131.25% | -85.3% |
| Total Long-Term Assets | $123.6M | $125.4M |
| YoY Change | -25.96% | -36.79% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $118.1M | $109.6M |
| Total Long-Term Assets | $123.6M | $125.4M |
| Total Assets | $241.7M | $235.0M |
| YoY Change | -31.3% | -46.09% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $14.64M | $9.038M |
| YoY Change | -18.79% | -54.14% |
| Accrued Expenses | $67.74M | $62.66M |
| YoY Change | -4.59% | -28.27% |
| Deferred Revenue | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $17.50M | $8.000M |
| YoY Change | -45.31% | -87.87% |
| Total Short-Term Liabilities | $99.87M | $79.70M |
| YoY Change | -19.95% | -57.6% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $17.18M | $34.61M |
| YoY Change | -49.58% | |
| Other Long-Term Liabilities | $155.2M | $9.415M |
| YoY Change | 1176.49% | -87.33% |
| Total Long-Term Liabilities | $172.4M | $44.03M |
| YoY Change | 272.88% | -40.75% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $99.87M | $79.70M |
| Total Long-Term Liabilities | $172.4M | $44.03M |
| Total Liabilities | $272.3M | $274.4M |
| YoY Change | -20.5% | -34.98% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.609B | -$1.610B |
| YoY Change | 3.61% | 4.15% |
| Common Stock | $1.578B | $1.570B |
| YoY Change | 1.03% | 0.7% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$30.58M | -$39.42M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $241.7M | $235.0M |
| YoY Change | -31.3% | -46.09% |
Cashflow Statement
| Concept | 2023 Q4 | 2023 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $614.0K | -$14.49M |
| YoY Change | -108.13% | -72.06% |
| Depreciation, Depletion And Amortization | $9.404M | $9.400M |
| YoY Change | -0.16% | -0.25% |
| Cash From Operating Activities | -$2.308M | -$7.170M |
| YoY Change | -95.78% | -121.21% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | $0.00 |
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | $0.00 | $0.00 |
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -1.290M | 50.00K |
| YoY Change | 128900.0% | -100.15% |
| NET CHANGE | ||
| Cash From Operating Activities | -2.308M | -7.170M |
| Cash From Investing Activities | 0.000 | 0.000 |
| Cash From Financing Activities | -1.290M | 50.00K |
| Net Change In Cash | -3.598M | -7.120M |
| YoY Change | -93.42% | -920.28% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$2.308M | -$7.170M |
| Capital Expenditures | $0.00 | $0.00 |
| Free Cash Flow | -$2.308M | -$7.170M |
| YoY Change | -95.78% | -121.21% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q3 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
760000 | usd |
| CY2022Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
760000 | usd |
| CY2023Q3 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
34613000 | usd |
| CY2022Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
34078000 | usd |
| CY2023Q3 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
56061000 | usd |
| CY2022Q4 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
57484000 | usd |
| CY2023Q3 | us-gaap |
Contract With Customer Refund Liability Noncurrent
ContractWithCustomerRefundLiabilityNoncurrent
|
40346000 | usd |
| CY2022Q4 | us-gaap |
Contract With Customer Refund Liability Noncurrent
ContractWithCustomerRefundLiabilityNoncurrent
|
40992000 | usd |
| CY2022Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.29 | |
| CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
188306350 | shares |
| CY2022Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
183882446 | shares |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26878000 | usd |
| CY2023Q3 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent | |
| CY2023Q3 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent | |
| CY2023Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
188313807 | shares |
| CY2023Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
188313807 | shares |
| CY2023Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | usd |
| CY2022Q3 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-906000 | usd |
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | usd | |
| us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-906000 | usd | |
| CY2023Q3 | us-gaap |
Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
|
0 | usd |
| CY2022Q3 | us-gaap |
Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
|
0 | usd |
| us-gaap |
Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
|
-524000 | usd | |
| us-gaap |
Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
|
0 | usd | |
| CY2023Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14489000 | usd |
| CY2023Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-14489000 | usd |
| CY2022Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-54096000 | usd |
| CY2022Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-54096000 | usd |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-52539000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-52539000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-88155000 | usd | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-88155000 | usd | |
| CY2023Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14489000 | usd |
| CY2022Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-54096000 | usd |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-52539000 | usd | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-88155000 | usd | |
| CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.08 | |
| CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.08 | |
| CY2022Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.29 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.28 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.28 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.48 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.48 | ||
| CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
188306350 | shares |
| CY2022Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
183882446 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
186643878 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
186643878 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
182375443 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
182375443 | shares | |
| CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
74008000 | usd |
| CY2022Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
7178000 | usd |
| CY2022Q1 | akba |
Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
|
367000 | usd |
| CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4536000 | usd |
| CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-63509000 | usd |
| CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22580000 | usd |
| CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6841000 | usd |
| CY2022Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
67000 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
29449000 | usd |
| CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
58937000 | usd |
| CY2022Q3 | akba |
Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
|
43000 | usd |
| CY2022Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3375000 | usd |
| CY2022Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-54096000 | usd |
| CY2022Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8259000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5230000 | usd |
| CY2023Q1 | akba |
Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan
StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan
|
34000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2489000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-19125000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3490000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11172000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-26807000 | usd |
| CY2023Q3 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
50000 | usd |
| CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1824000 | usd |
| CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14489000 | usd |
| CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-39422000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-52539000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-88155000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
1191000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
1246000 | usd | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
27032000 | usd | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
27032000 | usd | |
| akba |
Contractual Arrangement Royalties Agreement Noncash Interest Expense Income
ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome
|
0 | usd | |
| akba |
Contractual Arrangement Royalties Agreement Noncash Interest Expense Income
ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome
|
6352000 | usd | |
| akba |
Contractual Arrangement Royalties Agreement Noncash Royalty Revenue
ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue
|
1423000 | usd | |
| akba |
Contractual Arrangement Royalties Agreement Noncash Royalty Revenue
ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue
|
1195000 | usd | |
| akba |
Contract With Customer Non Cash Revenue Recognized
ContractWithCustomerNonCashRevenueRecognized
|
0 | usd | |
| akba |
Contract With Customer Non Cash Revenue Recognized
ContractWithCustomerNonCashRevenueRecognized
|
9550000 | usd | |
| akba |
Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
|
782000 | usd | |
| akba |
Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
|
3941000 | usd | |
| akba |
Noncash Interest Expense
NoncashInterestExpense
|
1318000 | usd | |
| akba |
Noncash Interest Expense
NoncashInterestExpense
|
1467000 | usd | |
| us-gaap |
Straight Line Rent
StraightLineRent
|
1221000 | usd | |
| us-gaap |
Straight Line Rent
StraightLineRent
|
1818000 | usd | |
| us-gaap |
Gain Loss On Contract Termination
GainLossOnContractTermination
|
825000 | usd | |
| us-gaap |
Gain Loss On Contract Termination
GainLossOnContractTermination
|
0 | usd | |
| us-gaap |
Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
|
0 | usd | |
| us-gaap |
Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
|
406000 | usd | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
1327000 | usd | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
10002000 | usd | |
| akba |
Excess Inventory Purchase Commitments Expense Reversal
ExcessInventoryPurchaseCommitmentsExpenseReversal
|
0 | usd | |
| akba |
Excess Inventory Purchase Commitments Expense Reversal
ExcessInventoryPurchaseCommitmentsExpenseReversal
|
14095000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7803000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
14808000 | usd | |
| us-gaap |
Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
|
0 | usd | |
| us-gaap |
Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
|
-1060000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-17692000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-28312000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-9238000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5365000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-10043000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-9798000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
8175000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-21031000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-9747000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-17420000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-13735000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-21534000 | usd | |
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
1128000 | usd | |
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
1771000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3738000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
2181000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-7227000 | usd | |
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-14820000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-21076000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-18475000 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
114000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-114000 | usd | |
| akba |
Proceeds From Refund Liability To Contract With Customer
ProceedsFromRefundLiabilityToContractWithCustomer
|
0 | usd | |
| akba |
Proceeds From Refund Liability To Contract With Customer
ProceedsFromRefundLiabilityToContractWithCustomer
|
40000000 | usd | |
| akba |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
0 | usd | |
| akba |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
7122000 | usd | |
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
84000 | usd | |
| us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
410000 | usd | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | usd | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
67000 | usd | |
| us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
24000000 | usd | |
| us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
33000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-23916000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
14599000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-44992000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-3990000 | usd | |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93169000 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
151839000 | usd |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
NATURE OF BUSINESS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Akebia Therapeutics, Inc., and it's subsidiaries, referred to as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Akebia</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">the Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, was incorporated in the State of Delaware in 2007. Akebia is a fully integrated biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease. The Company has one commercial product, Auryxia</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ferric citrate), which is approved by the U.S. Food and Drug Administration, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">FDA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with chronic kidney disease, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">CKD,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> on dialysis, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">DD-CKD</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and the treatment of iron deficiency anemia, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">IDA,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in adult patients with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CKD not on dialysis, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">NDD-CKD</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients for the improvement of hyperphosphatemia in such patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vadadustat, the Company’s lead investigational product candidate, is an investigational oral hypoxia-inducible factor prolyl hydroxylase, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">HIF-PH</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. On March 29, 2022, the Company received a complete response letter, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">CRL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, from the FDA, which provided that it could not approve the new drug application, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">NDA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, for vadadustat for the treatment of anemia due to CKD in adult patients in its present form. In October 2022, the Company submitted a Formal Dispute Resolution Request with the FDA and in May 2023, the Office of New Drugs, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">OND</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, denied the Company's appeal but provided a path forward for the Company to resubmit the NDA for vadadustat for the treatment of anemia due to CKD for dialysis dependent patients without the need for the Company to generate additional clinical data. In September 2023, the Company completed its resubmission to its NDA for vadadustat for the treatment of anemia due to CKD for dialysis dependent patients. In October 2023, the FDA acknowledged that the resubmission was complete, classified it as a Class 2 response and set a user fee goal date, or</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> PDUFA date</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, of March 27, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2023, the European Commission, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">EC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, approved the marketing authorization of vadadustat under the trade name Vafseo for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis. The marketing authorization of vadadustat under the trade name Vafseo for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis was subsequently approved in May 2023 in the United Kingdom, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">UK</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, by the Medicines and Healthcare products Regulatory Agency, in June 2023 in Switzerland by the Swiss Agency for Therapeutics Products, in March 2023 in Korea by the Ministry of Food and Drug Safety (under trade name Vadanem) and in September 2023 in Australia and Taiwan by the Therapeutic Goods Administration, or TGA, and Taiwan Food and Drug Administration, respectively. In May 2023, the Company entered into a License Agreement, or the Medice License Agreement, with MEDICE Arzneimittel Pütter GmbH & Co. KG, or Medice, pursuant to which the Company granted Medice an exclusive license to develop and commercialize vadadustat for the treatment of anemia in patients with CKD in the European Economic Area, the UK, Switzerland and Australia, or the Medice Territory. Vadadustat is also approved in Japan as a treatment for anemia due to CKD in both DD-CKD and NDD-CKD patients under the trade name Vafseo, and marketed and sold in Japan by Mitsubishi Tanabe Pharma Corporation, or MTPC. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from MTPC from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">HCR,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Royalty Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">MTPC Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, subject to certain caps and other terms and conditions (see Note 4 for additional information). The Company has not generated a profit to date, and may never generate profits, from product sales. Vadadustat and the Company’s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, commercializing Auryxia and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia in 2014 and revenue from sublicensing rights to Auryxia in Japan from the Company’s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">JT and Torii,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in December 2018. In addition, the Company continues to explore additional development opportunities to expand its pipeline and portfolio of novel therapeutics. If the Company does not successfully commercialize vadadustat, if approved, or any other potential product candidate, it may be unable to achieve profitability. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2023, the Company had cash and cash equivalents of approximately $46.5 million. Based on its current operating plan, the Company believes its cash resources and the cash the Company expects to generate from product, royalty and license revenues will be sufficient to fund its current operating plan for at least twelve months from the filing of this Quarterly Report on Form 10-Q. However, if the Company’s operating performance deteriorates significantly from the levels expected in the Company’s operating plan, or if vadadustat is not approved in the U.S., it would affect the Company’s liquidity and its ability to continue as a going concern in the future. The Company expects to finance future cash needs through </span></div>product revenue and royalty and license revenue and, if the Company believes its resources are insufficient to satisfy its liquidity requirements, the Company may seek to sell public or private equity, enter into new debt transactions, explore potential strategic transactions or a combination of these approaches. There can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund its operating plan for the period of time anticipated by the Company, or that additional funding will be available on terms acceptable to the Company, or at all. | ||
| CY2023Q3 | akba |
Number Of Commercial Products
NumberOfCommercialProducts
|
1 | commercialproduct |
| CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
46500000 | usd |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities as of and during the reported period. On an ongoing basis, management evaluates its estimates. Management bases its estimates and assumptions on historical experience when available and on various factors, including expected business and operational changes, sensitivity and volatility associated with the assumption that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of the assets and liabilities that are not readily apparent from other sources. In certain circumstances, management must apply significant judgment in this process. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management selects an amount that falls within that range of reasonable estimates. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known.</span></div>Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to: accrued expenses, right-of-use assets and liabilities, embedded debt derivative, refund liabilities to customers, other long-term liabilities, stock-based compensation expense and certain judgments regarding product and collaboration revenues. including various rebates, returns and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible asset and goodwill. | ||
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
0 | usd | |
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
29574000 | usd | |
| CY2023Q3 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd |
| us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd | |
| us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd | |
| CY2022Q3 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd |
| CY2023Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
46529000 | usd |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
90466000 | usd |
| CY2023Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
1648000 | usd |
| CY2022Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
2703000 | usd |
| CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
48177000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93169000 | usd |
| CY2022Q4 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
38102000 | usd |
| us-gaap |
Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
|
69822000 | usd | |
| akba |
Valuation Allowances And Reserves Adjustments Related To Prior Period Sales
ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
|
-1888000 | usd | |
| us-gaap |
Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
|
77047000 | usd | |
| CY2023Q3 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
28989000 | usd |
| CY2021Q4 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
35258000 | usd |
| us-gaap |
Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
|
76538000 | usd | |
| akba |
Valuation Allowances And Reserves Adjustments Related To Prior Period Sales
ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
|
-409000 | usd | |
| us-gaap |
Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
|
77474000 | usd | |
| CY2022Q3 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
33913000 | usd |
| CY2023Q3 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
0 | usd |
| CY2022Q3 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
5047000 | usd |
| CY2023Q3 | akba |
Contract With Customer Refund Liability Amortization Of Discount
ContractWithCustomerRefundLiabilityAmortizationOfDiscount
|
700000 | usd |
| akba |
Contract With Customer Refund Liability Amortization Of Discount
ContractWithCustomerRefundLiabilityAmortizationOfDiscount
|
2400000 | usd | |
| CY2022Q3 | akba |
Contract With Customer Refund Liability Amortization Of Discount
ContractWithCustomerRefundLiabilityAmortizationOfDiscount
|
1100000 | usd |
| akba |
Contract With Customer Refund Liability Amortization Of Discount
ContractWithCustomerRefundLiabilityAmortizationOfDiscount
|
2300000 | usd | |
| CY2023Q3 | akba |
Contract With Customer Refund Liability Amortization Of Deferred Gain
ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain
|
1000000 | usd |
| akba |
Contract With Customer Refund Liability Amortization Of Deferred Gain
ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain
|
3000000 | usd | |
| CY2022Q3 | akba |
Contract With Customer Refund Liability Amortization Of Deferred Gain
ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain
|
900000 | usd |
| akba |
Contract With Customer Refund Liability Amortization Of Deferred Gain
ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain
|
1800000 | usd | |
| CY2021Q1 | akba |
Contractual Arrangement Royalties Agreement Maximum Annual Royalty Payout Capacity
ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity
|
13000000 | usd |
| CY2021Q1 | akba |
Contractual Arrangement Royalties Agreement Maximum Aggregate Royalty Payout Capacity
ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity
|
150000000 | usd |
| CY2021Q1 | akba |
Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties
ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties
|
44800000 | usd |
| CY2021Q1 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
44800000 | usd |
| CY2023Q3 | akba |
Contractual Arrangement Royalties Agreement Interest Rate Effective Percentage
ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage
|
0 | |
| CY2022Q4 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
57484000 | usd |
| akba |
Contractual Arrangement Royalties Agreement Royalties Earned And Payable
ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable
|
1423000 | usd | |
| CY2023Q3 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
56061000 | usd |
| CY2023Q3 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
2640000 | usd |
| CY2022Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
7892000 | usd |
| CY2023Q3 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
15802000 | usd |
| CY2022Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
13676000 | usd |
| CY2023Q3 | us-gaap |
Inventory Net
InventoryNet
|
18442000 | usd |
| CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
21568000 | usd |
| CY2023Q3 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
848000 | usd |
| CY2022Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
610000 | usd |
| CY2023Q3 | akba |
Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
|
19290000 | usd |
| CY2022Q4 | akba |
Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
|
22178000 | usd |
| CY2023Q3 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
700000 | usd |
| CY2022Q3 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
2600000 | usd |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
1300000 | usd | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
10000000 | usd | |
| CY2023Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9000000 | usd |
| CY2022Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9000000 | usd |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
27000000 | usd | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
27000000 | usd | |
| CY2023Q3 | us-gaap |
Goodwill
Goodwill
|
59000000 | usd |
| CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
59000000 | usd |
| CY2023Q3 | us-gaap |
Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
|
0 | usd |
| CY2022Q4 | us-gaap |
Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
|
0 | usd |
| CY2023Q3 | akba |
Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
|
23834000 | usd |
| CY2022Q4 | akba |
Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
|
26268000 | usd |
| CY2023Q3 | akba |
Accrued Product Revenue Return Reserves Current
AccruedProductRevenueReturnReservesCurrent
|
3312000 | usd |
| CY2022Q4 | akba |
Accrued Product Revenue Return Reserves Current
AccruedProductRevenueReturnReservesCurrent
|
7789000 | usd |
| CY2023Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7204000 | usd |
| CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11481000 | usd |
| CY2023Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4861000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4744000 | usd |
| CY2023Q3 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3076000 | usd |
| CY2022Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3804000 | usd |
| CY2023Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
4648000 | usd |
| CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1886000 | usd |
| CY2023Q3 | akba |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
4156000 | usd |
| CY2022Q4 | akba |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
4310000 | usd |
| CY2023Q3 | akba |
Long Term Purchase Commitment Termination Fee Current
LongTermPurchaseCommitmentTerminationFeeCurrent
|
5000000 | usd |
| CY2022Q4 | akba |
Long Term Purchase Commitment Termination Fee Current
LongTermPurchaseCommitmentTerminationFeeCurrent
|
0 | usd |
| CY2023Q3 | akba |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
312000 | usd |
| CY2022Q4 | akba |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
5755000 | usd |
| CY2023Q3 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
617000 | usd |
| CY2022Q4 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
2751000 | usd |
| CY2023Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5644000 | usd |
| CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6989000 | usd |
| CY2023Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
62664000 | usd |
| CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
75777000 | usd |
| us-gaap |
Embedded Derivative Gain On Embedded Derivative
EmbeddedDerivativeGainOnEmbeddedDerivative
|
1100000 | usd | |
| CY2020Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | shares |
| CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
350000000 | shares |
| CY2023Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
350000000 | shares |
| CY2023Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2023Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
188313807 | shares |
| CY2023Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
188313807 | shares |
| CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
184135714 | shares |
| CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
184135714 | shares |
| CY2023Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | shares |
| CY2023Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.00001 | |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1800000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7800000 | usd | |
| CY2022Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3400000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
14800000 | usd | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
11775411 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.82 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y3M3D | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
4143813 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.83 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
5989 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
7.43 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
1299122 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
5.82 | ||
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
14614113 | shares |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.40 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y2M1D | ||
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2345000 | usd |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
8215979 | shares |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
6.52 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y9M18D | ||
| CY2023Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18876709 | shares |
| CY2022Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
18816539 | shares |
| CY2023Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1824000 | usd |
| CY2022Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3355000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7803000 | usd | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
14808000 | usd | |
| CY2023Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1200000 | usd |
| CY2022Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1800000 | usd |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
4400000 | usd | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
5400000 | usd | |
| CY2023Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1400000 | usd |
| CY2022Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1800000 | usd |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
4500000 | usd | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
5500000 | usd | |
| us-gaap |
Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
|
-500000 | usd | |
| CY2023Q2 | us-gaap |
Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
|
-500000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1421000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
5741000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
5819000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3613000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
16594000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1501000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1501000 | usd |
| CY2023Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
15093000 | usd |
| CY2023Q3 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P2Y11M12D | |
| us-gaap |
Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
|
45400000 | usd | |
| CY2023Q3 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2023Q3 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2023Q3 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2023Q3 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
